Identification of multiple genetic loci associated with RBC alloimmunization in mice


Received: July 15, 2022.
Accepted: October 28, 2022.

Citation: Arijita Jash, Heather L. Howie, Ariel M. Hay, Chance John Luckey, Krystalyn E. Hudson, Peter C. Thomson, Sarah J. Ratcliffe, Mark Smolkin, and James C. Zimring.
Identification of multiple genetic loci associated with RBC alloimmunization in mice.

Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors’ final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Identification of multiple genetic loci associated with RBC alloimmunization in mice

Arijita Jash¹², Heather L. Howie¹, Ariel M. Hay¹², Chance John Luckey¹, Krystalyn E. Hudson³, Peter C. Thomson⁴, Sarah J. Ratcliffe⁵, Mark Smolkin⁵, James C. Zimring¹².*

1. University of Virginia School of Medicine, Charlottesville VA
2. Carter Immunology Center, University of Virginia, Charlottesville VA
3. Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY
4. Sydney School of Veterinary Science, University of Sydney, Sydney, NSW, Australia
5. University of Virginia, Public Health Sciences, Division of Biostatistics, Charlottesville VA

*To whom all correspondence should be addressed.
Please address correspondence to:
James C. Zimring, University of Virginia School of Medicine, P.O. Box 801386, Charlottesville, VA 22908  email: jcz2k@virginia.edu

Body = 1500
Figures = 2
Tables = 0
References = 15

Running Head: Genetic Determinants of Immune Responses to RBCs

Acknowledgments: This work was supported in part by P01 HL132819 from the National Heart Lung and Blood Institute.

Conflicts of Interest: JCZ is an advisor for Rubius Therapeutics and a co-founder and CSO of Svalinn Therapeutics, neither of which were involved with the current studies.

Author Contributions: AJ and AMH performed the research. JCZ, CJL, and KEH conceived of the work and JCZ supervised the work. HLH processed genomics data, SJR and MS carried out statistical analysis, and PCT performed the QTL analysis - all authors were involved in data interpretation. JCZ wrote the manuscript with editorial input from other authors.

Data Sharing: Genomics and alloimmunization data available upon request.
Humoral immunization to RBC alloantigens can represent a barrier to ongoing transfusion therapy. Humans have a range of tendencies to become alloimmunized. On the extremes, some patients become immunized to multiple alloantigens after a single transfusion whereas others make no detectable alloantibodies after hundreds of transfusions.\(^1\) Although an oversimplification of a complex trait, humans have been described as being “responders” vs. “nonresponders” based upon their tendency to become alloimmunized.\(^1\) Alloimmunization against multiple antigens can complicate obtaining sufficient compatible units, leading to insufficient or delayed treatment, and mortality in severe cases. In addition to transfusion, engineered RBCs are now being developed to induce immunity (e.g. vaccines\(^2\) and tumor immunotherapy\(^3\)), or to suppress immunity (e.g. treatment of autoimmune disease).\(^4\) Thus, understanding factors that regulate immune responses to RBCs is important for multiple therapeutic approaches. Numerous murine studies have shown that transfused RBCs do not induce a significant alloantibody response unless recipients are first inflamed or transfused RBCs are damaged. These findings have translated into humans and constituted considerable progress in understanding environmental factors that regulate responder/nonresponder status. However, recipient genetics likely also play a role. Several human loci of interest have been identified\(^5\text{-}^7\), but achieving sufficient statistical power has been a challenge. Application of murine models to exploration of recipient genetics has not been carried out, since RBCs are only weakly immunogenic in the reported mouse models. Importantly, existing murine studies have almost exclusively used mice on a C57BL/6 (B6) background as recipients. We hypothesized that B6 mice represent a model of “nonresponders” and that the tendency to become alloimmunized after transfusion would vary across genetically distinct inbred strains. Herein, we demonstrate a continuum of humoral RBC alloimmunization tendency in different inbred strains of mice and identify six genetic loci that are associated with RBC alloimmunization through a genome wide association study (GWAS).
Thirteen different strains of mice, chosen to represent different phylogenetic arms of inbred mice, were each transfused with RBCs expressing either a model alloantigen (HOD) or the human K2 alloantigen at low copy number (KEL-K2Lo). Blood was collected, transfused, and IgG responses were measured as previously described.

HOD RBCs have repeatedly been shown to induce little to no IgG in otherwise untreated B6 mice (i.e., in the absence of recipient inflammation). KEL-K2Lo RBCs have been reported to not induce IgG in B6 mice even in the presence of inflammation, but rather lead to tolerance. Consistent with published findings, neither HOD nor KEL-K2Lo RBCs induced considerable IgG in B6 recipients (Figure 1). In contrast, there was wide variability of responsiveness across other strains, with similar (but not identical) patterns between HOD and KEL-K2Lo RBCs.

HLA differences in humans can regulate RBC alloimmunization to specific antigens based upon the differential ability of MHCII to present peptides from RBC alloantigens. However, differences in RBC alloimmunization across murine strains were not simply due to variant MHCII, since 129 mice consistently responded more strongly than B6 mice, and both have the same MHC haplotype (H-2b). Also, DBA2 mice have significantly higher average responses than seen in B6 mice that are congenic for the DBA2 H-2d MHC haplotype and are homozygous for H-2d on a B6 background (B6.H2d). Finally, all tested strains have the same amino acid sequence of murine orthologues of lysozyme (contained in HOD) and KEL, ruling out orthology to alloantigen as an independent variable.

Alloantibody responses and high-resolution SNP genotyping profiles were generated on 156 F2 mice from a 129S1xB6 F2 cross. F2 mice had a range of responses between the means of parental strains (Figure 2A). Quantitative trait locus (QTL) analysis [reviewed in reference 10] was performed on the F2 mice using alloantibody levels as a trait. At least 6 different QTL were identified (FDR < 0.01), on chromosomes 1, 7, 9, 11, 12, and the X chromosome, respectively (Figure 2B). An additional QTL on chromosome 17 approached the
cutoff for significance. The QTL on chromosome 1 appeared to indicate two, and potentially three different loci.

As a control for the QTL process, leukocytes from each mouse were also tested for expression of NK1.1 by flow cytometry. NK1.1 is expressed by B6 but not 129 mice and is encoded by the Klrb1c gene on chromosome 6 at position 129755448-128765604. QTL analysis mapped the NK1.1 gene to the correct position on chromosome 6 with extreme statistical significance (p < 10^{-22}) [Figure 2C], validating the QTL approach as well as the F2 cohort.

Together, the findings reported herein demonstrate genetic variability across inbred strains of mice regarding the tendency to mount a humoral immune response to a foreign antigen on transfused RBCs. This observation demonstrates that the common narrative that RBCs are intrinsically non-immunogenic in mice is an error born from studying only a single inbred recipient strain (i.e., B6). The current data demonstrate that, similar to humans, recipient genetics affect the tendency to become alloimmunized to RBC transfusion.

Interestingly, one of the few papers that reported transfused RBCs as being immunogenic, was an early report by Campbell-Lee et al., which used CBA mice as recipients. Although CBA mice are not in the current panel, they are closely related to C3H animals – the significance of these early findings regarding recipient genetics has likely been overlooked. Similarly, papers in RBC engineering that showed strong antibody responses used BALB/c or B6D2F1 mice. Thus, careful attention to recipient strain may help to resolve apparent contradictions in the literature, as well as leading to new understanding of the genetic regulation of RBC alloimmunization. This will be a fundamental consideration in translating RBC based immunotherapies into humans; murine studies should pay careful attention to the recipient strain being studied and arguably test a range of recipient strains to understand the landscape of potential responses.
 Genetic variation in immune responses to various antigens is not itself new. However, it is well understood that genetic determinants of immune response differ with regards to the nature of the antigen. Genetic variation of different murine strains in magnitude of antibody responses to sheep red blood cells (SRBCs) have previously been reported; however, QTL were not identified. More importantly, SRBCs are a strong xenoantigen that is fundamentally different than alloimmunization within the same species. To the best of our knowledge, the current study is the first analysis of immunogenetics of response to RBC alloantigens in mice.

Another potentially serious issue raised by the current findings is that the vast majority of knockout mice have been made on a 129 background and then backcrossed to B6. As we (and others) have documented, this approach is susceptible to mistaking the effects of traits inherited from 129 mice for effects of the knocked out gene. Even with many generations of backcrossing, genes flanking the knockout gene typically maintain genetics from the donor strain, in this case 129. Because 129 mice tend to respond to RBC antigens, any data from using knockout mice generated with 129 ES cells should consider the proximity of the knocked-out gene to the QTLs defined herein.

Identification of the precise genetic elements that regulate alloimmunization will require additional refinement of the QTL and experimentation through genetic modification. Although highly significant, the QTL generated by this approach are broad (i.e., 880 genes in QTL11). As such, more precise mapping and/or congenesis will be required to identify precise genetic elements. Potential translation into humans will require focused analysis of human genomes associated with alloimmunization; however, it is worth noting that QTL 7 contains ARAP1/STARD10, which was identified as associating with alloimmunization in human patients with sickle cell disease. Variation in human HLA correlates with alloimmunization to some RBC alloantigens and the QTL approaching statistical significance on Chr 17 may represent variation in mouse MHC. However, as above, the MHC seems neither necessary nor sufficient to regulate RBC alloimmunization as mice with the same H-2 haplotype have significantly
different average immune responses to RBC transfusion. Likewise, donor RBCs having a different MHC than recipient mice does not seem determinative, as there is a wide range of average responses for A/J, AKR/J, Balb/cByJ, C3H/HeJ, DBA/2J, FVB/NJ, and NOD/ShiLTJ strains even though each see the H-2b on HOD and KEL-K2 RBCs as foreign. Importantly, the QTL need not indicate immunoregulatory genes, as they could indicate variant amino acids in RBC proteins that are processed and presented in MHCII between donor and recipient strains. Due to linked recognition, such epitopes could come from proteins other than the transgenic alloantigens being studied.

In addition to generating new genetic regions of interest in alloimmunization (and immunology in general), the data contained herein widen our gaze of the immunogenic properties of RBCs, indicating that they are neither intrinsically immunogenic nor nonimmunogenic, and their effects are contextual with regards to recipient genetics. Understanding the genetics of RBC alloimmunization, and how it translates into humans, will be essential both to predicting and controlling RBC alloimmunization during transfusion therapy, as well as precision medicine in the use of modified RBCs as a cellular therapy with regards to recipient genetics.
References:


Figure Legends:

Figure 1: Genetically distinct mouse strains have different tendencies towards RBC alloimmunization. Each of the indicated strains were transfused with HOD (A) or KEL-K2Lo (B) RBCs and IgG responses were tested in serum at 21 days after transfusion. Serum was incubated with alloantigen expressing RBCs followed by a fluorescently labeled secondary antibody and median fluorescence intensity was determined by flow cytometry. As both alloantigen transgenic mice are on a B6 background, serum was also incubated with B6 RBCs and the MFI subtracted from values with alloantigen expressing target cells. MHC haplotypes of the mice used are [A/J (H-2^a), AKR/J (H-2^k), Balb/cByJ(H-2^d), BTBR(H-2^b), C57BL6/J(H-2^o), C3H/HeJ(H-2^e), DBA/2J(H-2^d), FVB/NJ(H-2^o), KK/HiJ(H-2^h), NOD/ShiLtJ(H-2^g7), 129S1/SVImJ(H-2^h), 129SX1/SvJ(H-2^h) ]. No antibodies to background antigens on B6 RBCs were detected and the MFI of B6 RBCs was subtracted from the MFIs of target RBCs expressing the indicated alloantigen. Negative values for IgG were determined to be nonbiologically relevant and were thus set to a value of zero. The combined results of three different experiments are shown, with samples sizes ranging from 13-15 mice. Statistical significance is defined as a Sidak-Bonferroni adjusted p<0.05 in pairwise comparisons estimated from a two-part model (logit & log-linear links) adjusted for experiment – each strain is compared to B6.H2d. Statistical significance is indicated by (*=<0.05) and (** < 0.001). No experimental results that were obtained with this approach were excluded from this figure. HOD and KEL-K2Lo mice were bred in the University of Virginia vivarium, all recipient mice were purchased from The Jaxson Laboratory (Bar Harbor, ME) and all procedures were carried out in compliance with approved IACUC protocols.
Figure 2: Identification of multiple genetic loci that associate with RBC alloimmunization. 156 F2 mice were each transfused with KEL-K2\textsubscript{L0} RBCs and alloantibodies were measured at 21 days post transfusion (A). For each animal, expression of NK1.1 was determined on splenocytes by flow cytometry (data not shown). QTL analysis was carried out using alloimmunization to RBCs (B) or NK1.1 expression (C) as the trait. Starting with a total of 11,125 SNPs, 3,220 differed between the B6 and 129 strains, with 3,118 remaining after filtering for informative markers. GWAS analysis used a linear model with a transformation $y = \log_e(\text{Pheno1} + 60)$ applied prior to data analysis and fitted using the lm function in R. From each SNP model fitted, the $p$-value form the $F$-test was extracted, and adjusted $p$-values (false discovery rate, FDR) were calculated using the p.adjust function in R. Manhattan plots were constructed with thresholds taken as FDR = 0.05 (suggestive) and FDR = 0.01 (significant). Back-transformed means for each SNP genotype (AA, AB and BB) along with their standard errors were calculated using the emmeans package in R. For chromosomes where at least one SNP with FDR < 0.05 was found, the most significant SNP in the chromosome was identified. To assess if any of the other ‘significant SNPs’ in the chromosome had any effect in addition to the most significant one, a linear model was fitted with the most significant SNP as well as the SNP to be tested. No formal adjustment for multiple tests was undertaken for this analysis.